W
Weiwei Chen
Researcher at Medical University of South Carolina
Publications - 9
Citations - 690
Weiwei Chen is an academic researcher from Medical University of South Carolina. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 3 publications receiving 572 citations.
Papers
More filters
Journal ArticleDOI
The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells
Sridharan Soundararajan,Weiwei Chen,Eleanor K. Spicer,Nigel S. Courtenay-Luck,Daniel J. Fernandes +4 more
TL;DR: The results suggest that AS1411 acts as a molecular decoy by competing with bcl-2 mRNA for binding to cytoplasmic nucleolin in these breast cancer cell lines, which interferes with the stabilization of bcl -2 mRNA by nucleolin and may be one mechanism by which AS 1411 induces tumor cell death.
Journal ArticleDOI
Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells
Sridharan Soundararajan,Li Wang,Vijayalakshmi Sridharan,Weiwei Chen,Nigel Courtenay-Luck,David R. Jones,Eleanor K. Spicer,Daniel J. Fernandes +7 more
TL;DR: Results provide evidence that plasma membrane nucleolin is a functional receptor for AS1411 in MV4-11 cells.
Journal ArticleDOI
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
Lian Xu,Chang Zou,Shanshan Zhang,Timothy Shun Man Chu,Yan Zhang,Weiwei Chen,Caini Zhao,Lin Yang,Zhiyuan Xu,Shaowei Dong,Hao Yu,Boyan Li,Xinyuan Guan,Yuzhu Hou,Feng Ming Kong +14 more
TL;DR: In this paper , a review of single-cell transcriptomics and spatial transcriptomics for the studies of the systemic tumor immune microenvironment (STIE) and their interactions is presented, which may reveal heterogeneity in immunotherapy responses as well as the dynamic changes essential for the treatment effect.
Journal ArticleDOI
Activity and Mechanism of Action of AS1411 in Acute Myeloid Leukemia Cells.
Weiwei Chen,Vijayalakshmi Sridharan,Sridharan Soundararajan,Yoko Otake,Robert K. Stuart,David R. Jones,Daniel J. Fernandes +6 more
TL;DR: This work demonstrates that AS 1411 has both cytostatic and cytotoxic effects on AML cells and underpins the dosing regime of AS1411 in the ongoing AML clinical trial.